natgillin/translations-raw huggingface dataset:
Patients must not take any medicines or products that contain methylxanthines (such as caffeine or theophylline) for at least 12 hours before receiving Rapiscan. 
Bolniki vsaj 12 ur pred dajanjem zdravila Rapiscan ne smejo uživati nobenih zdravil, ki vsebujejo metilksantine (npr. kofein ali teofilin).
It works by attaching to A2A adenosine receptors in the walls of the blood vessels in the heart, causing the blood vessels to widen and increasing blood flow into the heart muscle. 
Deluje tako, da se veže na receptorje adenozina A2A v stenah krvnih žil srca, kar povzroči, da se krvne žile razširijo in se poveča dotok krvi v srčno mišico.
Why has Rapiscan been approved? 
Zakaj je bilo zdravilo Rapiscan odobreno?
Rapiscan is for diagnostic use only. 
Zdravilo Rapiscan je samo za diagnostično uporabo.
Rapiscan is a solution for injection that contains the active substance regadenoson. 
Zdravilo Rapiscan je raztopina za injiciranje, ki vsebuje zdravilno učinkovino regadenozon.
For the full list of all side effects reported with Rapiscan, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rapiscan, glejte navodilo za uporabo.
Before this type of scan, the patient's heart is usually put under stress by exercise such as walking or running on a treadmill to help dilate (widen) the blood vessels in the heart and increase the blood flow to the heart muscle. 
Pred izvedbo te vrste slikanja se bolnikovo srce običajno izpostavi obremenitvi s telesno vadbo, kot sta hoja ali tek na tekočem traku, kar pripomore k razširitvi krvnih žil v srcu in povečanju dotoka krvi v srčno mišico.
How has Rapiscan been studied? 
Kako je bilo zdravilo Rapiscan raziskano?
How is Rapiscan used? 
Kako se zdravilo Rapiscan uporablja?
What is Rapiscan? 
Kaj je zdravilo Rapiscan?
What is Rapiscan used for? 
Za kaj se zdravilo Rapiscan uporablja?
This enables the blood flow in the heart to be seen more easily during myocardial perfusion imaging. 
Med slikanjem miokardne perfuzije je tako dotok krvi v srce bolje viden.
How does Rapiscan work? 
Kako zdravilo Rapiscan deluje?
(See section 4.4) 
(Glejte poglavje 4.4)
The duration of protection beyond 4 years is currently under investigation. 
Raziskovanje trajanja zaščite po več kot 4 letih trenutno poteka.
If not used within 6 hours it should be discarded. 
Če ni uporabljeno v 6 urah, ga je treba zavreči.
From a microbiological point of view, the vaccine should be used immediately. 
Z mikrobiološkega stališča je treba cepivo uporabiti takoj.
The clinical relevance of this data is not known. 
Klinična pomembnost teh podatkov ni znana.
It usually occurs in one part of the body and can last for several weeks. 
Po navadi se pojavi na enem delu telesa in lahko traja več tednov.
Chemical and physical in-use stability has been demonstrated for 24 hours at 30°C. 
Kemična in fizikalna stabilnost med uporabo sta dokazani za 24 ur na temperaturi 30 °C.
• you have a severe infection with a high temperature (fever). 
• če imate hudo okužbo z visoko temperaturo (vročino).
In these cases, the vaccination may have to be postponed until you have recovered. 
V takšnih primerih bo cepljenje morda treba odložiti, dokler ne okrevate.
Efficacy has not been assessed for the 0, 6-month schedule. 
Učinkovitost ni bila ocenjena za shemo 0 in 6 mesecev.
The first injection can be given from the age of 50 years onwards. 
Prvo injekcijo je mogoče dati v starosti od 50. leta naprej.
Most of these reactions were not long-lasting (median duration of 2 to 3 days). 
Večina teh učinkov ni trajala dolgo (mediano od 2 do 3 dni).
This medicinal product must not be mixed with other medicinal products. 
Zdravila se ne sme mešati z drugimi zdravili.
§ Not statistically significant 
§ Ni statistično značilno.
For adjuvant see also section 2. 
Za adjuvans glejte tudi poglavje 2.
• You will receive 2 injections with an interval of 2 months. 
• Dobili boste 2 injekciji v presledku 2 mesecev.
• Do not use this medicine after the expiry date which is stated on the label and carton. 
• Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli.
Concomitant use with other vaccines is not recommended due to lack of data. 
Sočasna uporaba z drugimi cepivi ni priporočljiva, zaradi pomanjkanja podatkov.
Make sure you finish the complete vaccination course. 
Poskrbite, da boste dokončali celotni ciklus cepljenja.
A total of 135 adults, of whom 73 
Skupno 135 odraslih, od katerih je bilo
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. 
Z namenom izboljšanja sledljivosti bioloških zdravil morata biti ime in serijska številka uporabljenega zdravila jasno zabeležena.
Laboratory confirmation of HZ cases was not part of the study procedures. 
Laboratorijska potrditev primerov HZ ni bila del postopkov študije.
Maladministration via the subcutaneous route may lead to an increase in transient local reactions. 
Nepravilna uporaba subkutano lahko poveča prehodne lokalne reakcije.
A minor infection such as a cold should not be a problem, but talk to your doctor first; 
Blažja okužba, na primer prehlad, ne bi smela biti težava, vendar se prej posvetujte z zdravnikom,
Speak to your doctor for more information. 
Za več informacij se posvetujte z zdravnikom.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 6 hours at 2°C to 8°C. 
Če ni uporabljeno takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme presegati 6 ur pri temperaturi od 2 °C - 8 °C.
Powder (gE antigen): 
Prašek (antigen gE):
Most of these side effects are mild to moderate in intensity and are not long-lasting. 
Večina teh neželenih učinkov je blagih do zmernih in niso dolgotrajni.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 21 March 2018 
Datum prve odobritve: 21. marec 2018
The studies were not designed to demonstrate efficacy in subgroups of frail individuals, including those with multiple comorbidities, although these subjects were not excluded from the studies. 
Študiji nista bili zasnovani za prikaz učinkovitosti v podskupinah slabotnih posameznikov, vključno s posamezniki s številnimi pridruženimi boleznimi, čeprav ti posamezniki iz študij niso bili izključeni.
Very common headache 
Zelo pogosti glavobol
This is a higher recurrence rate than generally reported in observational studies in unvaccinated individuals with a history of HZ. 
To je višja stopnja ponovitve, kot je na splošno poročano v opazovalnih študijah pri necepljenih posameznikih z zgodovino HZ.
Month 38** 
38. mesec**
Healthcare professionals therefore need to weigh the benefits and risks of HZ vaccination on an individual basis. 
Zdravstveni delavci morajo zato pretehtati koristi in tveganja cepljenja proti HZ za vsakega posameznika posebej.
The most frequently reported adverse reactions were pain at the injection site (68.1% overall/dose; 
Najpogosteje poročani neželeni učinki so bili bolečina na mestu injiciranja (68,1 % skupno/odmerek,
Month 3* 
3. mesec*
There were 9 reports of suspected HZ in 6 subjects over a one-year follow up period. 
V tej študiji je bilo 9 primerov domnevnega HZ pri 6 posameznikih v 1-letnem obdobju spremljanja.
Vaccine efficacy [95% CI] 
Učinkovitost cepiva (%) [95 % IZ]
The adjuvant (AS01B) is used to improve the body's response to the vaccine. 
Adjuvans (AS01B) je uporabljen za izboljšanje telesnega odziva na cepivo.
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription, or have recently received any other vaccine. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta, ali če ste pred nedavnim dobili katero koli drugo cepivo.
Subcutaneous administration is not recommended. 
Subkutana uporaba ni priporočljiva.
Number of HZ cases 
Število primerov HZ
The vaccine is for prophylactic use only and is not intended for treatment of established clinical disease. 
Cepivo je namenjeno samo za profilaktično uporabo in ne za zdravljenje že razvite klinične bolezni.
• you are allergic (hypersensitive) to the active substances or any of the other ingredients of this vaccine (listed in section 6). 
• če ste alergični (preobčutljivi) na učinkovine ali katero koli sestavino tega cepiva (navedeno v poglavju 6).
Shake gently until the powder is completely dissolved. 
Rahlo pretresite, dokler se prašek povsem ne raztopi.
For intramuscular injection only, preferably in the deltoid muscle. 
Samo za intramuskularno injiciranje, po možnosti v deltoidno mišico.
Fatigue and malaise may occur following administration (see section 4.8). 
Po cepljenju se lahko pojavita utrujenost in slabo počutje (glejte poglavje 4.8).
As a consequence of the high vaccine efficacy against HZ, a low number of breakthrough cases were accrued, and it was therefore not possible to draw firm conclusions on these study objectives. 
Zaradi velike učinkovitosti cepiva proti HZ je bilo zajeto le majhno število prebojnih primerov, zato trdni sklepi o teh raziskovalnih ciljih niso bili mogoči.
The vaccines should be administered at different injection sites. 
Cepivi je treba injicirati na različni mesti.
N GMC (mIU/ml) (95% CI) 
N GMC (m i.e./ml) (95 % IZ)
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this vaccine. 
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden dobite to cepivo.
This helps your immune system (the body's natural defences) stay prepared to fight the virus and protect you against shingles and its complications. 
To pomaga imunskemu sistemu (naravni obrambi organizma), da ostane pripravljen na boj z virusom in vas tako zaščiti pred pasovcem in njegovimi zapleti.
An immunological correlate of protection has not been established; therefore the level of immune response that provides protection against HZ is unknown. 
Imunološki korelat zaščite ni ugotovljen, zato raven imunskega odziva, ki zagotavlja zaščito pred HZ,
Reactions reported as severe lasted 1 to 2 days. 
Hudi neželeni učinki so trajali 1 do 2 dni.
Non-clinical data show that AS01B induces a local and transient activation of the innate immune system through specific molecular pathways. 
Predklinični podatki kažejo, da AS01B inducira lokalno in prehodno aktivacijo prirojenega imunskega sistema preko specifičnih molekularnih poti.
• skin infections, weakness, muscle paralysis and loss of hearing or vision - these are less common. 
• okužbe kože, šibkost, ohromelost mišic (paraliza) in izguba sluha ali vida - ti so manj pogosti.
The administration of Shingrix to immunocompromised subjects should be based on careful consideration of potential benefits and risks. 
Uporaba cepiva Shingrix pri imunokompromitiranih osebah mora temeljiti na skrbni oceni možnih koristi in tveganj.
The use of Shingrix should be in accordance with official recommendations. 
Uporaba cepiva Shingrix mora biti v skladu z uradnimi priporočili.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website 
To navodilo za uporabo je na voljo v vseh uradnih jezikih EU/EGP na spletni strani Evropske agencije za zdravila.
This protein is not infectious. 
Beljakovina ni kužna.
Shingrix may have a minor influence on the ability to drive and use machines in the 2-3 days following vaccination. 
Cepivo Shingrix ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev 2-3 dni po cepljenju.
CI Confidence interval 
IZ Interval zaupanja.
As with other vaccines, an adequate immune response may not be elicited in these individuals. 
Kot pri drugih cepivih, zadosten imunski odziv morda ne bo dosežen pri teh posameznikih.
Therefore tell the doctor or nurse if you fainted with a previous injection. 
Zato morate zdravniku ali medicinski sestri povedati, če ste kdaj v preteklosti omedleli, ko ste dobili injekcijo.
The primary vaccination schedule consists of two doses of 0.5 ml each: an initial dose followed by a second dose 2 months later. 
Osnovna shema cepljenja obsega dva odmerka po 0,5 ml: začetni odmerek, ki mu sledi drugi odmerek čez 2 meseca.
• The other ingredients are: 
• Druge sestavine cepiva so:
you may get pain which can last for months or years and may be severe. 
Ko mehurji pasovca izginejo, se lahko pojavijo bolečine, ki lahko trajajo več mesecev ali let in so lahko hude.
The European Medicines Agency has deferred the obligation to submit the results of studies with Shingrix in one or more subsets of the paediatric population in prevention of Varicella Zoster Virus reactivation (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij s cepivom Shingrix za eno ali več podskupin pediatrične populacije za preprečevanje reaktivacije virusa varicella zoster (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Adults aged 50-69 years may experience more side effects compared to adults aged ≥ 70 years. 
Odrasli v starosti od 50 do 69 let imajo lahko več neželenih učinkov kot odrasli v starosti ≥ 70 let.
Number of evaluable subjects 
Število ocenljivih preiskovancev
If either is observed, do not reconstitute the vaccine. 
Če opazite eno ali drugo, cepiva ne rekonstituirajte.
• You will be informed when you should come back for the second dose of Shingrix. 
• Povedali vam bodo, kdaj morate priti po naslednji odmerek cepiva Shingrix.
No cases of visceral disease or stroke were reported during these studies. 
V teh študijah niso zabeležili nobenega primera visceralne bolezni ali možganske kapi.
Change the needle so that you are using a new needle to administer the vaccine. 
Zamenjajte iglo, tako da boste za injiciranje cepiva uporabili novo iglo.
Efficacy against HZ-related complications other than PHN 
Učinkovitost proti zapletom, povezanim s HZ (drugi kot PHN)
• Shingrix is given as an injection into a muscle (usually in the upper arm). 
• Cepivo Shingrix se daje kot injekcija v mišico (po navadi na nadlahti).
As with all vaccines, Shingrix may not fully protect all people who are vaccinated. 
Tako kot velja za vsa cepiva, tudi cepivo Shingrix ne more povsem zaščititi vseh cepljenih oseb.
• scars where the blisters have been. 
• brazgotine na mestih, kjer so bili mehurji.
The use of Shingrix in subjects with other confirmed or suspected immunosuppressive or immunodeficient conditions is under investigation. 
Uporabo cepiva Shingrix pri osebah z drugimi potrjenimi ali domnevnimi stanji imunske supresije ali imunske pomanjkljivosti trenutno raziskujejo.
The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation. 
Imetnik dovoljenja za promet z zdravilom mora prvi PSUR za to zdravilo predložiti v 6 mesecih po pridobitvi dovoljenja za promet.
After reconstitution, the vaccine should be used promptly; if this is not possible, the vaccine should be stored in a refrigerator (2°C - 8°C). 
Cepivo je treba injicirati takoj po rekonstituciji; če to ni mogoče, ga morate shraniti v hladilniku (2 °C - 8 °C).
• long-lasting nerve pain - called post-herpetic neuralgia or PHN. 
• dolgotrajne bolečine živcev - imenujemo jih postherpetična nevralgija (s kratico PHN).
Subjects with a history of HZ prior to vaccination 
Preiskovanci z anamnezo HZ pred cepljenjem
As with other vaccines, vaccination with Shingrix should be postponed in subjects suffering from an acute severe febrile illness. 
Tako kot velja za druga cepiva, je treba tudi cepljenje s cepivom Shingrix odložiti pri osebah z akutno, hudo febrilno boleznijo.
MARKETING AUTHORISATION NUMBER(S) EU/1/18/1272/001 - 1 vial and 1 vial EU/1/18/1272/002 - 10 vials and 10 vials 
EU/1/18/1272/001 - 1 viala in 1 viala EU/1/18/1272/002 - 10 vial in 10 vial
Post-hoc analysis of efficacy against confirmed HZ undertaken in patients with common conditions (chronic kidney disease, chronic obstructive pulmonary disease, coronary artery disease, depression or diabetes mellitus), indicates that the vaccine efficacy is aligned with the overall HZ efficacy. 
Post hoc analiza učinkovitosti proti potrjenemu HZ pri preiskovancih s pogostimi osnovnimi boleznimi (kronična ledvična bolezen, kronična obstruktivna pljučna bolezen, bolezen koronarnih arterij, depresija, sladkorna bolezen) kaže, da se učinkovitost sklada s celokupno učinkovitostjo proti HZ.
Adverse reactions reported are listed according to the following frequency: Very common 
Opisani neželeni učinki so navedeni po naslednji razvrstitvi pogostnosti:
10 vials: powder (antigen) 10 vials: suspension (adjuvant) 
10 vial: prašek (antigen) 10 vial: suspenzija (adjuvans)
The benefit of Shingrix in the prevention of PHN can be attributed to the effect of the vaccine on the prevention of HZ. 
Korist cepiva Shingrix za preprečevanje PHN je mogoče pripisati učinku cepiva na preprečevanje HZ.
Efficacy results against HZ and PHN observed in the modified Total Vaccinated Cohort (mTVC), i.e. excluding adults who did not receive the second dose of vaccine or who had a confirmed diagnosis of HZ within one month after the second dose, are presented in Table 1 and Table 2, respectively. 
Rezultati učinkovitosti proti HZ in PHN, ugotovljeni v prilagojeni celotni cepljeni kohorti (mTVCmodified Total Vaccinated Cohort), tj. izključujoč tiste odrasle, ki niso prejeli drugega odmerka cepiva ali so imeli potrjeno diagnozo HZ v enem mesecu po drugem odmerku, so predstavljeni v preglednicah 1 in 2.
The median anti-gE antibody concentration was greater than 7-fold above the baseline pre-vaccination median concentration. 
Mediana koncentracija protiteles proti gE je bila več kot 7-krat večja od izhodiščne mediane koncentracije pred cepljenjem.
The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of appearance. 
Rekonstituirano cepivo je treba pregledati glede prisotnosti tujih delcev in/ali spremenjenega videza.
The need for booster doses following the primary vaccination schedule has not been established (see section 5.1). 
Potreba po obnovitvenih odmerkih po opravljenem osnovnem cepljenju ni bila dokazana (glejte poglavje 5.1).
were ≥50 years of age, received at least one dose of Shingrix, which was shown to be immunogenic and well-tolerated. 
73 oseb starih ≥ 50 let, je prejelo vsaj en odmerek cepiva Shingrix, ki se je izkazalo za imunogeno in so ga prejemniki dobro prenašali.
• Suspension for 1 dose in a vial 
• Suspenzijo za 1 odmerek v viali
Shingrix is available in a pack size of 1 vial of powder plus 1 vial of suspension or in a pack size of 10 vials of powder plus 10 vials of suspension. 
Cepivo Shingrix je na voljo v velikosti pakiranja z 1 vialo praška in 1 vialo suspenzije ali v velikosti pakiranja z 10 vialami praška in 10 vialami suspenzije.
However, do not drive or use machines if you are feeling unwell. 
Toda če se ne počutite dobro, ne vozite in ne upravljajte strojev.
The powder and suspension should be inspected visually for any foreign particulate matter and/or variation of appearance. 
Prašek in suspenzijo je treba pregledati glede prisotnosti tujih delcev in/ali spremenjenega videza.
Shingrix can be given at the same time as other vaccines. 
Cepivo Shingrix se lahko uporabi hkrati z drugimi cepivi.
The immune responses to Shingrix were evaluated in a subset of subjects from the phase III efficacy studies ZOE-50 [humoral immunity and cell-mediated immunity (CMI)] and ZOE-70 (humoral immunity). 
Imunske odzive na cepivo Shingrix so ocenili v podskupini preiskovancev iz študij učinkovitosti III. faze ZOE-50 [humoralna imunost in celično posredovana imunost (CMI - cell-mediated immunity)] in ZOE-70 (humoralna imunost).
• After you have had chickenpox, the virus that caused it stays in your body in nerve cells. 
• Ko prebolite norice, ostane virus, ki jih povzroča, v telesu v živčnih celicah.
Shingles may lead to complications. 
Pasovec lahko povzroči zaplete.
Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. 
Po vsakem cepljenju ali celo pred njim se lahko pojavi sinkopa (omedlevica) kot psihološki odziv na injiciranje z iglo.
Rare hypersensitivity reactions including rash, urticaria, angioedema1 
Redki preobčutljivostne reakcije vključno z izpuščajem, urtikarijo, angioedemom1
• allergic reactions including rash, hives (urticaria), swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing (angioedema) 
• alergijske reakcije vključno z izpuščajem, koprivnico (urtikarijo), oteklostjo obraza, jezika ali grla, ki lahko povzroči težko požiranje ali dihanje (angioedem).
Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. 
Med znaki alergijske reakcije so lahko srbeč izpuščaj na koži, zasoplost in otekanje obraza ali jezika.
The glycoprotein E is a protein present in the Varicella Zoster Virus. 
Glikoprotein E je beljakovina v virusu varicella zoster.
If flexibility in the vaccination schedule is necessary, the second dose can be administered between 2 and 6 months after the first dose (see section 5.1). 
Če je potrebna prilagodljivost cepilne sheme, se drugi odmerek lahko da med 2 in 6 mesecev po prvem odmerku (glejte poglavje 5.1).
The median frequency of gE-specific CD4[2+] T cells was greater than 3.7-fold above baseline prevaccination median frequency. 
Mediana pogostnost za gE specifičnih celic T CD4[2+] je bila več kot 3,7-krat večja od izhodiščne mediane pogostnosti pred cepljenjem.
The burden-of-illness (BOI) score incorporates the incidence of HZ with the severity and duration of acute and chronic HZ-related pain over a 6 month period following rash onset. 
Ocena bremena bolezni (BOI - burden-of-illness) združuje pojavnost HZ z izrazitostjo in trajanjem akutnih in kroničnih s HZ povezanih bolečin med 6-mesečnim obdobjem po pojavu izpuščaja.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or post-natal development (see section 5.3). 
Študije na živalih ne kažejo neposrednih ali posrednih škodljivih učinkov na nosečnost, embrionalni/fetalni razvoj, porod ali postnatalni razvoj (glejte poglavje 5.3).
Immunogenicity in subjects receiving 2 doses of Shingrix 6 months apart 
Imunogenost pri preiskovancih, ki so prejeli 2 odmerka cepiva Shingrix v presledku 6 mesecev
The safety and efficacy of Shingrix in children and adolescents have not been established. 
Pediatrična populacija Varnost in učinkovitost cepiva Shingrix pri otrocih in mladostnikih nista bili dokazani.
This will maximise the protection offered by Shingrix. 
Tako boste dosegli največjo zaščito, ki jo lahko ponudi cepivo Shingrix.
• The powder is white. 
• Prašek je bele barve.
4.7 Effects on ability to drive and use machines No studies on the effects of Shingrix on the ability to drive and use machines have been performed. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Študij o vplivu cepiva Shingrix na sposobnost vožnje in upravljanja strojev niso izvedli.
Add the entire contents of the syringe into the vial containing the powder. 
Dodajte celotno vsebino injekcijske brizge v vialo, ki vsebuje prašek.
INFORMATION IN BRAILLE Justification for not including Braille accepted. 
INFORMACIJE V BRAILLOVI PISAVI Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
The powder and the suspension must be reconstituted prior to administration. 
Prašek in suspenzijo je treba pred uporabo rekonstituirati.
What you need to know before you receive Shingrix 3. 
Kaj morate vedeti, preden boste dobili cepivo Shingrix 3.
• swollen glands in the neck, armpit or groin 
• otekle bezgavke na vratu, pazduhi ali dimljah